CD34+ Hematopoietic Stem and Progenitor Cells (HSPCs) From Different Tissue Sources for Cell Therapy
High-quality starting material is important when developing cellular therapeutics. HSPCs are used as precursor material for the ex vivo expansion of genetically manipulated cells for cell therapy; however, the question of what source material is best for stem and progenitor cell types capable of therapeutic expansion and adoptive transplantation continues to be a topic of debate.
This white paper will discuss:
- The effects of various mobilization strategies
- The functional differences of CD34+ cells derived from bone marrow, cord blood, mobilized peripheral blood
- The factors that can significantly influence potency and downstream impact of cellular therapies (donor selection considerations, cell isolation and biopreservation procedures)